Primary drug treatment for glaucoma: Beta-blockers versus other medications

Survey of Ophthalmology

Volumn 47, Issue 1, 2002, Pages 63-67

  Stamper, Robert L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Beta blockers; Compliance; Cost; Glaucoma; Side effects

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; DRUG PRESERVATIVE; LATANOPROST; LEVOBUNOLOL; PROSTAGLANDIN DERIVATIVE; PURITE; QUINIDINE; TIMOLOL; TRAVOPROST; UNCLASSIFIED DRUG; UNOPROSTONE ISOPROPYL ESTER;

BRADYCARDIA; BRONCHOSPASM; DOSE RESPONSE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; CARBONIC ANHYDRASE INHIBITORS; DRUG COSTS; GLAUCOMA; HUMANS; OPHTHALMIC SOLUTIONS; PATIENT COMPLIANCE; PROSTAGLANDINS;

EID: 0036152567     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(01)00286-7     Document Type: Review

References (41)

1. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States
2. Acute episode of asthma following topical administration of betaxolol eyedrops
3. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension
4. Effects of timolol maleate on tear flow in human eyes
5. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics
6. Nephrolithiasis with dorzolamide
7. Apparent central nervous system depression in infants after the use of topical brimonidine
8. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide
9. Topical timolol decreases plasma high-density lipoprotein cholesterol level
10. Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men
11. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents
12. Improved lung function tests on changing from topical timolol: Non-selective beta-blockade impairs lung function tests in elderly patients
13. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: A 30-day comparison with latanoprost
14. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction
15. Effect of dorzolamide on corneal endothelial function in normal human eyes
16. Topical dorzolamide-induced hypotony and ciliochoroidal detachment in patients with previous filtration surgery
17. Falls in elderly patients with glaucoma
18. Brimonidine: A new alpha2-adrenoreceptor agonist for glaucoma treatment
19. Beta-blocker eyedrops and nocturnal arterial hypotension
20. Reduction of IOP with latanoprost
21. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost
22. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1- year results in glaucoma patients
23. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit
24. Irreversible corneal decompensation in patients treated with topical dorzolamide
25. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: Dosing, efficacy, and safety evaluation of a novel compound for glaucoma management
26. Topical timolol and the nursing mother
27. Clinical experience with latanoprost: A retrospective study of 153 patients
28. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias
29. Timolol transitory manifestation of dry eyes in long-term treatment
30. Timolol-induced bronchospasm in asthmatic bronchitis
31. Influence of systemic beta blocker therapy on the safety and efficacy of ophthalmic application of brimonidine or timolol
32. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure
33. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure
34. Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker
35. Corneal toxicity associated with latanoprost
36. Severe systemic toxicity caused by brimonidine drops in an infant with presumed juvenile xanthogranuloma
37. Latanoprost and herpes simplex keratitis
38. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients
39. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color
40. Timolol maleate: Efficacy and safety